Enveric Biosciences, Inc. (ENVB)
- Previous Close
0.9380 - Open
0.9200 - Bid 0.8576 x 100
- Ask 0.9455 x 100
- Day's Range
0.8994 - 0.9500 - 52 Week Range
0.6490 - 6.9800 - Volume
58,364 - Avg. Volume
4,443,441 - Market Cap (intraday)
6.575M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-8.0900 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Apr 23, 2008
- 1y Target Est
8.00
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
www.enveric.comRecent News: ENVB
Performance Overview: ENVB
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENVB
Valuation Measures
Market Cap
6.75M
Enterprise Value
-324.84k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.45
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.02
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-86.20%
Return on Equity (ttm)
-197.47%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.46M
Diluted EPS (ttm)
-8.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
2.29M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.9M
Research Analysis: ENVB
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell